StockData
Turn Therapeutics Inc. logo

Turn Therapeutics Inc. (TTRX) stock

TTRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/30
$8.89+0.34 (+3.98%)

Close on Nov 18, 2026Market cap $264.82MP/E –Yield –

Turn Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Turn Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$7.05M. For fiscal 2025 it was -$5.86M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.86M–
FY2024Dec 31, 2024-$1.80M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.98M–
Q2 FY2026Jun 30, 2026-$1.63M–
Q1 FY2026Mar 31, 2026-$1.25M–
Q4 FY2025Dec 31, 2025-$2.19M–
Q3 FY2025Sep 30, 2025-$1.91M–
Q2 FY2025Jun 30, 2025-$1.37M–
Q1 FY2025Mar 31, 2025-$385.00K–
Q4 FY2024Dec 31, 2024-$328.96K–
Q3 FY2024Sep 30, 2024-$672.99K–

More Turn Therapeutics figures

See a number that looks wrong?